Sophos will showcase its latest AI-driven solutions at its dedicated booth in Hall 23, Booth 50. The company will also have a ...
Sophos, a global leader of innovative security solutions for defeating cyberattacks, today announced that Aparna Williams has ...
For CRN’s Cybersecurity Week 2025, we’re looking at big moves in the MDR market this year including major vendor acquisitions ...
Discover the top 10 EDR tools for CIOs in 2025 that enhance endpoint protection, accelerate threat investigations, and reduce ...
Sophos, a global leader of innovative security solutions for defeating cyberattacks, today announced the launch of Sophos Advisory Services, a suite of security testing services designed to identify ...
By Ross Anderson, Sophos BU Executive at Duxbury NetworkingIssued by Duxbury NetworkingJohannesburg, 01 Oct 2025 Ross Anderson, Sophos BU Executive at Duxbury Networking. (Image: Duxbury Networking) ...
Copy, export, import, delete, document and compare policies and profiles in Intune and Azure with PowerShell script and WPF UI. Import ADMX files and registry settings with ADMX ingestion. View and ...
Results of the POSITIVE study assessing the treatment with tildrakizumab showed sustained improvements in skin clearance, psychological well-being, and improved partner quality of life in adults with ...
The U.S. Cybersecurity and Infrastructure Security Agency (CISA) has published an analysis of the malware deployed in attacks exploiting vulnerabilities affecting Ivanti Endpoint Manager Mobile (EPMM) ...
The study did not meet the primary endpoint of change from baseline in mean daily oral corticosteroid dose at week 48. Topline data were announced from a phase 3 trial evaluating efzofitimod in ...
Positive high-level results from a pre-specified interim analysis of the Phase III TULIP-SC trial in patients with systemic lupus erythematosus (SLE) showed that the subcutaneous (SC) administration ...
Investing.com -- aTyr Pharma (NASDAQ:ATYR) stock fell 80% after the company announced that its Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis failed to meet its primary endpoint. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback